Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01183364 · ClinicalTrials.gov registry record · Phase 1
A Dose Escalation Study of STA-9090 and Docetaxel in Patients With Solid Tumors
A Phase 1 study, sponsored by Synta Pharmaceuticals.
- Completed
- Registry status
- Phase 1
- Development phase
- 27
- Enrollment target
NCT01183364: Completed Phase 1 study, sponsored by Synta Pharmaceuticals.
NCT01183364 is a Phase 1 study that has completed, run by Synta Pharmaceuticals. The registered enrollment target is 27 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT01183364, a Phase 1 study, has completed, sponsored by Synta Pharmaceuticals.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 27 participants
- Enrollment target
Study Summary
This is an open-label, Phase 1, dose-escalation study to determine the recommended doses of STA-9090 (ganetespib) and docetaxel for the treatment of subjects with solid tumor malignancies. The safety and tolerability of the treatment will also be evaluated.
Interventions
- DRUG STA-9090 (ganetespib) with Docetaxel
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 27 participants |
| Start Date | 2010-07 |
| Est. Completion | 2013-05 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01183364
The ClinicalTrials.gov registry entry for NCT01183364 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 27 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Synta Pharmaceuticals, which has 21 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which STA-9090 (ganetespib) with Docetaxel is the first listed.
NCT01183364 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01183364 about?
NCT01183364 is a clinical study titled "A Dose Escalation Study of STA-9090 and Docetaxel in Patients With Solid Tumors". This is an open-label, Phase 1, dose-escalation study to determine the recommended doses of STA-9090 (ganetespib) and docetaxel for the treatment of subjects with solid tumor malignancies. The safety and tolerability of the treatment will also be evaluated.
What is the current status of trial NCT01183364?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 27 participants. The study started on 2010-07. Estimated completion is 2013-05.
What interventions are being tested in trial NCT01183364?
The interventions under investigation include: STA-9090 (ganetespib) with Docetaxel (DRUG).
Who is sponsoring clinical trial NCT01183364?
This trial is sponsored by Synta Pharmaceuticals, which has 21 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.